The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology—A Case Report and Review of the Literature

Hematological abnormalities are the most common early symptoms of Gaucher disease (GD), with an increased risk of hematopoietic system malignancies reported in patients with GD. GD may be associated with monoclonal and polyclonal gammopathies; however, the mechanism of association of GD with multiple myeloma (MM) remains uncertain. Enzyme replacement therapy (ERT) has been shown to improve patients’ cytopenia and it seems to facilitate anti-myeloma therapy in patients with co-occurring GD and MM. Although it is necessary to demonstrate the deficiency of enzymatic activity, as well as using genetic tests to finally diagnose GD, due to changes in the blood count image, bone marrow biopsy is still a frequent element of the GD diagnosis procedure. The diagnosis of GD is often delayed, mainly due to the heterogeneity of the histopathological picture of bone marrow biopsy or overlapping hematological abnormalities. Unrecognized and untreated GD worsens the response of a patient with an oncological disease to targeted treatment. We present a literature review, inspired by the case of a Caucasian patient initially diagnosed with MM and later confirmed with comorbid GD type 1 (GD1). We would like to point out the problem of underdiagnosis and delay in patients with GD.

[1]  M. Cappellini,et al.  Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry , 2022, American journal of hematology.

[2]  S. Revel-Vilk,et al.  Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease , 2022, Internal medicine journal.

[3]  M. Yuseff,et al.  Alterations in Lysosome Homeostasis in Lipid-Related Disorders: Impact on Metabolic Tissues and Immune Cells , 2021, Frontiers in Cell and Developmental Biology.

[4]  S. Packman,et al.  Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results , 2021, American journal of hematology.

[5]  J. Szer,et al.  Hematological manifestations and complications of Gaucher disease , 2021, Expert review of hematology.

[6]  J. Charrow,et al.  Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. , 2021, Molecular genetics and metabolism.

[7]  P. Mistry,et al.  Gaucher disease: Basic and translational science needs for more complete therapy and management. , 2020, Molecular genetics and metabolism.

[8]  S. Revel-Vilk,et al.  A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. , 2020, Hematology. American Society of Hematology. Education Program.

[9]  P. Steele,et al.  Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States , 2020, American journal of medical genetics. Part C, Seminars in medical genetics.

[10]  H. Avet-Loiseau,et al.  Risk and Response-Adapted Treatment in Multiple Myeloma , 2020, Cancers.

[11]  J. Szer,et al.  Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease , 2020, Orphanet Journal of Rare Diseases.

[12]  Shaji K. Kumar,et al.  Multiple myeloma current treatment algorithms , 2020, Blood Cancer Journal.

[13]  A. Chadburn,et al.  Synchronous multiple myeloma and Gaucher disease. , 2020, Hematology/oncology and stem cell therapy.

[14]  M. Dhodapkar,et al.  Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. , 2020, Molecular genetics and metabolism.

[15]  N. Therville,et al.  Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses , 2020, Cancers.

[16]  L. Poll,et al.  Gaucher Disease in Bone: From Pathophysiology to Practice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  K. Fiedoruk,et al.  Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development , 2019, International journal of molecular sciences.

[18]  M. Pfreundschuh,et al.  Saposin C is a frequent target of paraproteins in Gaucher disease‐associated MGUS/multiple myeloma , 2018, British journal of haematology.

[19]  M. Foster,et al.  Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial , 2018, American journal of hematology.

[20]  T. Betsuyaku,et al.  Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. , 2018, Lung cancer.

[21]  A. Canbay,et al.  Hepatocellular carcinoma in Gaucher disease: an international case series , 2018, Journal of Inherited Metabolic Disease.

[22]  O. Goker-Alpan,et al.  Gaucheromas: When macrophages promote tumor formation and dissemination. , 2018, Blood cells, molecules & diseases.

[23]  B. Győrffy,et al.  Tumor‐associated macrophages (TAMs) depend on ZEB1 for their cancer‐promoting roles , 2017, The EMBO journal.

[24]  J. Szer,et al.  Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. , 2017, Molecular genetics and metabolism.

[25]  D. Hughes,et al.  Lysosomal Storage Disorders and Malignancy , 2017, Diseases.

[26]  J. Stirnemann,et al.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.

[27]  M. Dhodapkar,et al.  Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. , 2016, The New England journal of medicine.

[28]  G. Castaman,et al.  Hematological manifestations and complications of Gaucher disease , 2016, Expert review of hematology.

[29]  J. Marugan,et al.  Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages , 2015, Aging cell.

[30]  S. Karlsson,et al.  Inhibition of UDP‐glucosylceramide synthase in mice prevents Gaucher disease‐associated B‐cell malignancy , 2015, The Journal of pathology.

[31]  S. Işıksoy,et al.  Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question , 2014, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[32]  T. Park,et al.  Chronic myeloid leukemia with marked splenomegaly and pseudo-Gaucher cells , 2013, Blood research.

[33]  A. Mehta,et al.  Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. , 2013, Blood cells, molecules & diseases.

[34]  A. Sohani,et al.  Pseudo‐Gaucher cells in disseminated mycobacterial infection , 2013, American journal of hematology.

[35]  D. Roggenbuck,et al.  Acute inflammatory neuropathy with monoclonal anti-GM2 IgM antibodies, IgM-κ paraprotein and additional autoimmune processes in association with a diffuse large B-cell non-Hodgkin's lymphoma , 2013, BMJ Case Reports.

[36]  S. Morad,et al.  Ceramide-orchestrated signalling in cancer cells , 2012, Nature Reviews Cancer.

[37]  D. Schatz,et al.  Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. , 2012, Blood.

[38]  G. Baysoy,et al.  Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response? , 2011, The Turkish journal of pediatrics.

[39]  S. Plon,et al.  Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. , 2011, American journal of human genetics.

[40]  Y. Baruch,et al.  Gaucher's disease type I: a disease masked by the presence of abnormal laboratory tests common to primary liver disease. , 2010, European journal of gastroenterology & hepatology.

[41]  M. Machaczka,et al.  Treatment of multiple myeloma in patients with Gaucher disease , 2009, American journal of hematology.

[42]  G. Rennert,et al.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients , 2009, American journal of hematology.

[43]  J. Charrow,et al.  Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 , 2009, Genetics in Medicine.

[44]  J. M. Aerts,et al.  ‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature , 2008, Journal of Inherited Metabolic Disease.

[45]  C. Hollak,et al.  Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature , 2008, Annals of Hematology.

[46]  N. Khurana,et al.  Pseudo-Gaucher cells in Hb E disease and thalassemia intermedia , 2007, Hematology.

[47]  J. Yee,et al.  Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among Hematologists–Oncologists and an opportunity for early diagnosis and intervention , 2007, American journal of hematology.

[48]  C. Hollak,et al.  Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease , 2007, British journal of haematology.

[49]  H. Ida,et al.  Pseudo-Gaucher Cell Proliferation Associated with Myelodysplastic Syndrome , 2007, International journal of hematology.

[50]  J. Charrow,et al.  Gaucher disease and cancer incidence: a study from the Gaucher Registry. , 2005, Blood.

[51]  Fernando A. Arosa,et al.  Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC‐class II: monocytes from Gaucher disease patients as a model , 2005, British journal of haematology.

[52]  L. Boon,et al.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. , 2004, American journal of clinical pathology.

[53]  A. Lebeau,et al.  Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature. , 2002, Blood.

[54]  R. Proia,et al.  Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. , 2002, The Journal of clinical investigation.

[55]  N. Radin The Development of Aggressive Cancer: A Possible Role for Sphingolipids , 2002, Cancer investigation.

[56]  K. Possinger,et al.  Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria , 2000, Annals of Hematology.

[57]  A. J. Stewart,et al.  Pseudo-Gaucher cells in myelodysplasia. , 1999, Journal of clinical pathology.

[58]  R. Hartsock,et al.  Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin's disease. , 1987, American journal of clinical pathology.

[59]  M. Machaczka,et al.  Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1. , 2015, Folia histochemica et cytobiologica.

[60]  M. Pandey,et al.  Immunological cells and functions in Gaucher disease. , 2013, Critical reviews in oncogenesis.

[61]  D. Hughes,et al.  Gaucher disease and myeloma. , 2013, Critical reviews in oncogenesis.

[62]  T. Taddei,et al.  Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. , 2013, Critical reviews in oncogenesis.

[63]  W. Cheung,et al.  Type I Gaucher disease following chemotherapy for light chain multiple myeloma. , 2007, Internal medicine.

[64]  D. Häussinger,et al.  Increased incidence of cancer in adult Gaucher disease in Western Europe. , 2006, Blood cells, molecules & diseases.

[65]  S. Rajkumar,et al.  MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. , 2005, Hematology. American Society of Hematology. Education Program.

[66]  A. Brautbar,et al.  Effect of enzyme replacement therapy on gammopathies in Gaucher disease. , 2004, Blood cells, molecules & diseases.

[67]  G. Rossi,et al.  Pseudo-Gaucher plasma cells in the bone marrow of a patient with monoclonal gammopathy of undetermined significance. , 1997, Haematologica.

[68]  N. Rushton,et al.  Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. , 1997, QJM : monthly journal of the Association of Physicians.

[69]  A. Saven,et al.  Misuse of marrow examination in the diagnosis of Gaucher disease. , 1990, Blood.

[70]  P. Anderson,et al.  Phenotypic and Genetic Variation , 1980 .